AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00072384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00072384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00072384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT03281772 — intervention group
Intervention type: OTHER
Intervention: Clinical Decision Software - provider portal
Description: As noted in Arms
Study NCT03281772 — intervention group
Intervention type: OTHER
Intervention: Clinical Decision Software - patient portal
Description: As noted in Arms
Study NCT04295577 — intervention group
Intervention type: OTHER
Intervention: Niraparib
Description: Niraparib - Niraparib is an oral, highly selective PARP-1 and -2 inhibitor. However, it also inhibits other members of the PARP family, including PARP 3, -4, -10, 12, -14, and -15\[13\].
Study NCT01492348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS UP
Description: The STEPS UP intervention enhances RESPECT-Mil in several ways:~1. Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~2. Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, \& primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~3. Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~4. Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components.
Study NCT01492348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OUC
Description: Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist.
Study NCT01635829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
Study NCT01635829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
Study NCT01635829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
Study NCT04198831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustion.
Study NCT04198831 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients receiving sham acupuncture and sham mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and CV8, CV12 and bilateral ST36 were selected for moxibustion. Same Hwato acupuncture device was used to blind the subjects, but do not puncturing into the skin and do not have the deqi sensation. The surface temperature of acupoints was maintained at 37℃± 1℃ for moxibustion.
Study NCT01368263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given SC
Study NCT01368263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO
Study NCT01368263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO
Study NCT01368263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Standard chemotherapy
Study NCT01368263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT01982695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study NCT01982695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Study NCT02965404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study NCT02965404 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control live attenuated varicella vaccine
Description: The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
Study NCT02965404 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: diluent of lyophilized vaccine
Description: The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
Study NCT02104024 — intervention group
Intervention type: OTHER
Intervention: Contrast Enhanced Ultrasound Scanning
Study NCT03122691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cannabis
Description: Cannabis will be self-administered by study participants
Study NCT03397043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein intake (dose)
Description: Protein intake, in the form of crystalline amino acids, will range between 0.2-3.0 g/kg/d
Study NCT04528316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilates Core Stability Exercises program
Description: Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~* Stage I: Warm-up: consists of four Pilates motions:~  1. Breathing:~ 2. Rolling back:~ 3. Coccyx-curl:~ 4. Hundred breathing:~* Stage II: Work-out: consists of twelve Pilates motions:~  1. Single leg stretch:~ 2. Straight leg raise:~ 3. Basic bridge:~ 4. Bridging variation:~ 5. Quadruped:~ 6. Clap with seal motion~ 7. Mermaid twist:~ 8. Swimming:~ 9. Double leg stretch:~ 10. Shoulder bridge:~ 11. Swan dive:~ 12. Leg full front:~* Stage III: Cool-down: consists of three Pilates motions:~  1. Rest position:~ 2. Cat with arm/leg extension:~ 3. Breathing:
Study NCT04528316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Core Stability Exercises program
Description: Twenty patients will receive Pilates core stability exercises program ONLY. Total Period: 12 Weeks~Stages: Three stages:~* Stage I: Warm-up: consists of four Pilates motions:~  1. Breathing:~ 2. Rolling back:~ 3. Coccyx-curl:~ 4. Hundred breathing:~* Stage II: Work-out: consists of twelve Pilates motions:~  1. Single leg stretch:~ 2. Straight leg raise:~ 3. Basic bridge:~ 4. Bridging variation:~ 5. Quadruped:~ 6. Clap with seal motion~ 7. Mermaid twist:~ 8. Swimming:~ 9. Double leg stretch:~ 10. Shoulder bridge:~ 11. Swan dive:~ 12. Leg full front:~* Stage III: Cool-down: consists of three Pilates motions:~  1. Rest position:~ 2. Cat with arm/leg extension:~ 3. Breathing:
Study NCT04528316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Program
Description: Total Period: 12 Weeks. The designed HUMAC program will work on the modified clinical test of sensory integration of balance (mCTSIB) with eyes open and with eyes closed, the center of pressure (COP) and the limit of stability test (LOS).
Study NCT04528316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordination
Description: Total Period: 12 Weeks. Coordination will be assessed using BOT2, Bilateral coordination (Sub test No.4) composed of 7 items and Upper-Limb coordination (Sub test No.7) composed of 7 items too.~The raw scores are recorded first then it is converted into point scores, then subtest total point score is obtained by adding point scores.
Study NCT02357225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
Study NCT01518647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
Study NCT01518647 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
Study NCT04025541 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
Study NCT02983045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Description: NKTR 214 + nivolumab at 5 dosage levels.
Study NCT02983045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion Doublet: Combination of NKTR-214 + nivolumab
Description: Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
Study NCT02527824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Irinotecan, S-1
Description: Treatment will be delivered every 2 weeks~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day1-7
Study NCT03373942 — intervention group
Intervention type: OTHER
Intervention: Choroidal thickness measurements with SD-OCT device
Study NCT02983045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Description: 1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
Study NCT02983045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Description: Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
Study NCT03318198 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanged Attending Supervision
Description: Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
Study NCT03318198 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
Study NCT00773357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guanfacine
Description: 3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
Study NCT00773357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02631577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ]
Description: Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
Study NCT02631577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
Study NCT02631577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
Study NCT01707745 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravitreal Bevacizumab
Study NCT03738423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500
Description: Administered subcutaneous (SC)
Study NCT03738423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3500-Matching Placebo
Description: Administered subcutaneous (SC)
Study NCT02576119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176, Placebo (Part 1)
Description: The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
Study NCT02576119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176, Moxifloxacin, Placebo (Part 2)
Description: Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
Study NCT00933790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Description: Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
Study NCT00933790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Description: Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
Study NCT04083820 — intervention group
Intervention type: DRUG
Intervention: semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study NCT00816790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR \< 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
Study NCT00816790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/Tazobactam
Description: Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
Study NCT03280147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-day course of antibiotics
Description: Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned.
Study NCT03280147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day course of antibiotics
Description: Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned.
Study NCT00604825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Study NCT00604825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK232802
Study NCT00604825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREMARIN
Study NCT00722280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand Transplantation
Description: This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants.
Study NCT00145769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short Course Adjuvent Chemotherapy
Description: Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
Study NCT00145769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long Course Adjuvant Chemotherapy
Description: Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
Study NCT00145769 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short Course Radiotherapy
Description: 25 Gy in 5 fractions over 5 days.
Study NCT00145769 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long Course Radiotherapy
Description: 50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
Study NCT00145769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemotherapy
Description: 5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
Study NCT00145769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initial Surgery
Description: Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
Study NCT04458675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant capsule
Description: The capsule vibration mechanically stimulates the inner wall of the GI and stimulates motility
Study NCT04458675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A biodegradable capsule, which visually similar to the Vibrant active capsule
Study NCT02509377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Fetal Repair of Myelomeningocele
Description: Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
Study NCT06718712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower body resistance training
Description: The RT protocol was performed using a unilateral knee-extension machine. To reduce potential sources of bias to exercise order, subjects alternated the starting leg for each training session.
Study NCT00103285 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy
Study NCT00103285 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Some patients undergo cranial radiotherapy
Study NCT00103285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04500769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise
Description: Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
Study NCT02070679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Study NCT03349619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol plus Carboxymethyl-β-Glucan
Description: Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks